SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is seeing significant upward momentum fueled by reports of major insider and political stock purchases alongside a reinstated buy rating from BofA. Community sentiment is overwhelmingly bullish, with many traders discussing a rotation from hardware into software and positioning for a potential squeeze as the stock reclaims key technical levels.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing significant volatility driven by a broader semiconductor sell-off and investor concerns over memory industry capacity, despite analysts recently raising price targets citing robust demand for AI infrastructure. The community remains sharply divided, with many retail investors viewing the pullback as a buying opportunity while others express anxiety over macro headwinds and potential sector overextension.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global Holdings is trending as investors digest a string of beat-and-raise earnings reports and an emerging partnership with OpenAI, while community discussions highlight a sharp divide between those holding for long-term growth and those frustrated by persistent selling pressure and share-based compensation. Sentiment remains split between retail investors eager for a breakout toward higher price targets and short-term traders attempting to capitalize on the stock's cyclical volatility and recent liquidity events.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate whether its current valuation reflects a deep-value opportunity or a value trap, with the community closely tracking its pivot into agentic AI orchestration and enterprise integration partnerships. While many participants express frustration over persistent share price weakness and perceived market manipulation, others are aggressively accumulating shares, pointing to the company's strong cash position, lack of debt, and potential for long-term growth as the market rotates toward quality AI software.

Trio-Tech International engages in the provision of third-party semiconductor testing and burn-in services. It operates through the following segments: Semiconductor Back-End Solutions (SBS) and Industrial Electronics. The SBS segment is focused on the sale of burn-in and reliability test equipment used in the back-end manufacturing processes of semiconductors. Its equipment includes burn-in systems, burn-in boards, and related equipment that is used in the testing of structural integrity of integrated circuits. The Industrial Electronics segment consists of designing, manufacturing, and distributing a range of tests, processes, and other equipment used in the manufacturing processes of customers in various industries in the consumer and industrial market. The company was founded in 1958 and is headquartered in Los Angeles, CA.

Trio-Tech International

Trio-Tech International is experiencing significant volatility and high trading volume as investors debate its valuation relative to larger semiconductor testing peers. The community is sharply divided, with some highlighting recent contract wins and capacity expansion as signs of a long-term rerating, while others caution against the stock's parabolic move and potential for a sharp reversal.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is currently trending as investors weigh its long-term growth potential in AI-powered defense systems and autonomous drone warfare against recent volatility and sector-wide de-risking. The community is actively debating the company's competitive moats, the impact of federal budget allocations for unmanned systems, and whether current price levels represent an accumulation opportunity for a key player in modern military technology.

Agilysys, Inc. operates as a technology company. It offers innovative software for point-of-sale, payment gateway, reservation and table management, guest offers management, property management, inventory and procurement, analytics, document management, and mobile and wireless solutions and services to the hospitality industry. The firm also serves the gaming industry for both corporate and tribal, hotels resort and cruise, foodservice management, and the restaurant, university, and healthcare sectors. The company was founded in 1963 and is headquartered in Alpharetta, GA.

Agilysys, Inc

Agilysys is trending following a strong quarterly earnings report that featured a revenue beat and upward-revised forward guidance, fueling investor confidence in its subscription model and enterprise technology. The community is actively discussing the company's growth trajectory and momentum within the hospitality software sector, with many participants monitoring the stock for potential breakouts.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Relay Therapeutics Inc

Relay Therapeutics is currently trending as the community scrutinizes recent clinical data releases and the company's long-term competitive position, with some investors debating its potential for future growth against broader market volatility.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is experiencing significant momentum driven by a recent FDA priority review for its hypertension drug, baxdrostat, and a landmark manufacturing investment in the U.S. that has bolstered investor confidence. The community is actively discussing the stock's long-term growth potential and pipeline strength, particularly in oncology, while monitoring its strategic expansion efforts as a major player in the global pharma landscape.

Dakota Gold Corp. operates as a gold exploration and development company. It is focused on new gold discoveries and opportunities that build on the legacy of the Homestake District. The company was founded in 2017 is headquartered in Lead, SD.

Dakota Gold Corp

Dakota Gold Corp. is trending as investors react to new assay results from its Richmond Hill drill campaign, with the community actively debating the company's growth potential against the backdrop of equity financing and dilution concerns. The stock remains a focus for those tracking exploration progress in the historic Homestake District, though sentiment is split between bullish long-term outlooks and frustration over recent price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Canaccord Genuity Group Raises Sagimet Biosciences (NASDAQ:SGMT) Price Target to $49.00

Canaccord Genuity Group raised their target price on Sagimet Biosciences from $28.00 to $49.00 and gave the stock a 'buy' rating in a research note on Monday...

Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise

Sagimet Biosciences (NASDAQ:SGMT) said it is sharpening its strategic focus on developing differentiated therapies for patients with moderate to severe acne, with plans to advance its lead fatty acid...

Guggenheim Lowers Sagimet Biosciences (NASDAQ:SGMT) Price Target to $25.00

Guggenheim cut their target price on Sagimet Biosciences from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday...

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with technicals showing strong momentum.read more...

Why Sagimet Biosciences Stock Is Soaring Today

Key PointsSagimet Biosciences is developing a handful of drugs, but its priority is acne therapies...

Biotech Breakthroughs and Energy Deals Send These Stocks Soaring

A powerful wave of dealmaking, clinical breakthroughs, and infrastructure buildouts is driving renewed momentum with companies spanning energy, biotech, semiconductors, and AI ecosystems delivering headline-making developments. $USEG, $QUIK, $KBLB, $YAAS, $SGMT, $DKI, $GLND

<ul class="summary-bullets"><li>Sagimet plans to launch a Phase 3 U.S. trial of Denifanstat in the second half of 2026 following positive late-stage results in China, which showed a favorable safety profile.</li><li>The biotech firm priced a public offering of about 29.2 million shares of its Series A common stock at $6 per share, a 2.4% premium over its closing price on Friday.</li><li>Sagimet said the combined cash from the offering and its existing reserves should fund its acne programs through 2028.</li></ul>Shares of Sagimet Biosciences (SGMT) jumped more than 40% on Monday, breaking the 200-day moving average for the first time since early February, after the company priced its latest share offering at a premium and reported positive progress on its acne drug.<a href="https://stocktwits.com/symbol/SGMT">SGMT shares</a> recorded their biggest intraday gains in more than 27 months, rising to their highest levels in over 5 months.<img src="https://news.stocktwits-cdn.com/SGMT_jpg_9df53f672c.webp" alt="SGMT.jpg">Source: TradingView<h2 class="st-heading-2">$175M Offering To Boost Acne Treatment Pipeline</h2>Sagimet priced a public offering of about 29.2 million shares of its Series A common stock at $6 per share, aiming to raise roughly $175 million in gross proceeds. This represented a 2.4% premium to the stock’s closing price on Friday. The offering is expected to close around April 28, 2026.The clinical-stage biotech firm plans to use the funds to advance its pipeline, including a Phase 3 trial of its lead drug candidate Denifanstat for acne. Proceeds will also support the development of TVB-3567, a small-molecule inhibitor of fatty acid synthase (FASN) for acne treatment.Sagimet said the combined cash from the offering and its existing reserves should fund its acne programs through 2028, including key trial readouts. The remaining funds will be used for general corporate purposes, including clinical development, working capital, and operating expenses.<h2 class="st-heading-2">Denisfanstat Acne Treatment In Focus</h2>Sagimet is advancing its acne treatment pipeline, with plans to launch a Phase 3 U.S. trial of Denifanstat in the second half of 2026. The move follows positive late-stage results in China, where the once-daily oral therapy showed good safety and sustained improvement in patients with moderate to severe acne.The company is also progressing its broader pipeline. Sagiment announced plans to move its TVB-3567, currently in a Phase 1 trial, into Phase 2 studies later this year. Meanwhile, development in metabolic dysfunction-associated steatohepatitis (MASH) is expected to be paused until the company secures non-dilutive funding.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier, while message volumes on the platform remained ‘extremely high.’One user said the company’s acne treatment “has blockbuster potential.”<stembedurl>https://stocktwits.com/Expharmaguy/message/651485936</stembedurl>Another user said SGMT is “now a $50-100 value stock” given the “resoundingly positive phase 3” trial.<stembedurl>https://stocktwits.com/Market_Max/message/651490482</stembedurl>The stock has gained around 40% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-elon-musk-pay-package-share-registration-what-it-means/cZBNYDmReP3">TSLA Stock In Spotlight As EV Maker Registers Shares Tied To Elon Musk’s 2018 Pay Package – Retail Sees Imminent Sell-Off</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on technology background. INTC and AMD hit fresh records on Thursday. (Image source: Getty Images)

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?

The firm announced positive late-stage results in China for its lead drug candidate to treat acne, and priced its $175M offering at a premium. 

Equity

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Current Price	$6.66
Prev Close	$6.90
Open	$6.89
Dividend Yield	0.00%
50-Day Moving Average	$6.15
Beta	0.00
Avg. Volume	3.02M
PE Ratio	-4.96

52-Week High	$11.41
52-Week Low	$3.15
Market Capitalization	$422.17M
EPS (Annual)	-$1.58
Price to Book	2.12
Revenue Per Employee	$0.00

SGMT
Sagimet Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMT News

SGMTSagimet Biosciences Inc